Johnson and Johnson: The single-dose new coronapneumonia candidate vaccine has a powerful protective effect.

Study: A study published in the journal Nature shows that Johnson and Johnson's research with the SARS-CoV-2 vaccine can trigger a strong immune response to prevent subsequent infections.
several preclinical studies have shown that The Single-Dose New Coronary Pneumonia Candidate Vaccine has a strong protective effect, published in the journal Nature, shows that the SARS-CoV-2 vaccine used in Johnson and Johnson's research can cause a strong immune response to prevent follow-up infections now in the United States and Belgium, the first phase 1/2a clinical trial in humans; Johnson) (NYSE: JNJ) (the "Company") (the "Company") today announced that several preclinical studies have shown that the company's main candidate vaccine prevents people from contracting the new coronapneumonia virus SARS-CoV-2. According
to data published in the journal Nature, preclinical studies have shown that the company's research using adenovirus serotonin 26 (Ad26) vector vaccine can cause a strong immune response (as demonstrated by "neutralizing antibodies"), successfully prevent follow-up infections, and provide complete or near-complete virus protection against non-human primates (NHP) lungs."
based on valid data, the first clinical trial of the 1/2a phase candidate vaccine Ad26.COV2.S (conducted in healthy volunteers) has been launched in the United States and Belgium. Dr Paul Stoffels, Vice Chairman of the
Executive Committee and Chief Technology Officer, said: "We are pleased to see these preclinical data as they show that our SARS-CoV-2 vaccine candidate (single dose) produces a strong antibody response and provides protection.
the results of the study gave us a lot of confidence, and we are also advancing vaccine development and high-end production, launching phase 1/2a trials in July and planning to launch Phase 3 trials in September.
" ambitious Janssen New Crown Pneumonia Clinical Trial Program includes Phase 1/2a clinical trials and Phase 3 clinical trials that will evaluate single-dose and dual-dose Ad26.COV2.S therapies through parallel studies. the
1/2a trial will assess the safety, reactive (anticipated vaccination responses, such as swelling or pain) and immunogenicity of Ad26.COV2.S for more than 1,000 healthy adults aged 18 to 55, as well as adults aged 65 and over.
also plans to conduct phase 2a studies in the Netherlands, Spain and Germany and 1 in Japan.
for more information about these studies, please visit:
is in active discussions with partners as it plans its Phase 3 clinical development program for new crown pneumonia, with the goal of launching a critical phase 3 single-dose vaccine-to-place-controlled clinical trial in September, subject to provisional data from Phase 1 and Phase 2 trials and regulatory approval.
, the company also plans to launch a phase 3 clinical trial parallel to a placebo for a two-dose vaccine.
designanding and launching the Phase 3 pilot program for new crown pneumonia, the company will also highlight the number of people disproportionately affected by the new crown outbreak.
trials in the United States will include typically Hispanic, Hispanic/Latino and over-65 participants.
preclinical study was conducted by researchers at Beth Israel Deaconmedical Center, or "BIDMC", in partnership with companies such as Johnson and Johnson's Janssen Pharmaceuticals as part of their ongoing efforts to accelerate the development of the SARS-CoV-2 vaccine. "Preclinical data based on the Work of Johnson and Johnson highlight the potential of this SARS-CoV-2 vaccine candidate," said Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at the
BIDMC and Ragon Institute.
in addition, the data suggest that antibody levels may be biomarkers for vaccine-mediated protection. "In these studies, the researchers first used a prototype vaccine to immunize non-human primates and then challenged non-human primates with SARS-CoV-2 infection,"
.
scientists found that Ad26.COV.S(an article in the journal Nature called Ad26-S.PP) among the seven prototype vaccines tested in the study caused the highest level of SARS-CoV-2 neutralizing antibodies.
antibody levels are associated with protective levels, confirming previous observations and suggesting that they may be potential biomarkers for vaccine-mediated protection.
six non-human primates that received a single Ad26.COV2.S immunity were exposed to SARS-CoV-2 and did not detect the virus in the lower respiratory tract, and only one of them showed very low levels of the virus in the nasal swab at two points in time. "As we work together to combat the new crown outbreak, we remain firmly committed to achieving our goal of providing a safe and effective vaccine to the world," said Dr. Mathai Mammen, global head of Johnson and Johnson's Jansen research and development team at
.
our preclinical results give us reason to be optimistic, and we have launched our first clinical trial in humans.
we are pleased to enter a new phase of research and development efforts for the new Crown Pneumonia vaccine.
we know that, if successful, the vaccine could be developed quickly, mass-produced and made available around the world.
", "The company has a fundamental responsibility to provide the safest and most effective possible products to patients, consumers and healthcare providers."
Johnson and Johnson takes a scientific, ethical and values-based evidence-based approach to healthcare safety, making decisions and taking action that prioritizes the well-being of patients and consumers, with transparency as a top priority.
as Johnson and Johnson continues to advance the clinical development of SARS-CoV-2, the company continues to improve its manufacturing capabilities and actively engages with global strategic partners to support global access.
Johnson and Johnson aims to achieve its goal of providing more than 1 billion doses of safe and effective vaccines worldwide by 2021.
under other transaction agreements HHSO10020170018C, the program is funded in whole or in part from federal funds provided by the Office of the Assistant Secretary-General for Preparation and Response and the Biomedical Advanced Research and Development Authority.
.